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ABSTRACT
Introduction: Around 17% of general practitioner
(GP) consultations are for musculoskeletal conditions,
which will rise as the population ages. Patient direct
access to physiotherapy provides one solution, yet
adoption in the National Health Service (NHS) has been
slow.
Setting: A pilot, pragmatic, non-inferiority, cluster
randomised controlled trial (RCT) in general practice
and physiotherapy services in the UK.
Objectives: Investigate feasibility of a main RCT.
Participants: Adult patients registered in participating
practices and consulting with a musculoskeletal
problem.
Interventions: 4 general practices (clusters)
randomised to provide GP-led care as usual or the
addition of a patient direct access to physiotherapy
pathway.
Outcomes: Process outcomes and exploratory
analyses of clinical and cost outcomes.
Data collection: Participant-level data were collected
via questionnaires at identification, 2, 6 and 12 months
and through medical records.
Blinding: The study statistician and research nurses
were blinded to practice allocation.
Results: Of 2696 patients invited to complete study
questionnaires, 978 participated (intervention group
n=425, control arm n=553) and were analysed.
Participant recruitment was completed in 6 months.
Follow-up rates were 78% (6 months) and 71%
(12 months). No evidence of selection bias was
observed. The direct access pathway was used by 90%
of patients in intervention practices needing
physiotherapy. Some increase in referrals to
physiotherapy occurred from one practice, although
waiting times for physiotherapy did not increase
(28 days before, 26 days after introduction of direct
access). No safety issues were identified. Clinical and
cost outcomes were similar in both groups.
Exploratory estimates of between group effect (using
36-item Short Form Health Survey (SF-36) Physical
Component Summary (PCS)) at 6 months was −0.28
(95% CI −1.35 to 0.79) and at 12 months 0.12 (95%
CI −1.27 to 1.51).
Conclusions: A full RCT is feasible and will provide
trial evidence about the clinical and cost-effectiveness
of patient direct access to physiotherapy.
Trial registration number: ISRCTN23378642.
BACKGROUND
In the UK, primary care is struggling to meet
the current record demand from patients.
General practitioners (GPs) now do an esti-
mated 370 million consultations each year,
60 million more than 5 years ago,1 which
equates to a 16% increase in workload since
2007.2 Musculoskeletal problems account for
around 17% of GP consultations3 and given
the ageing population, the demand for mus-
culoskeletal healthcare is set to rise further.4
Strengths and limitations of this study
▪ This was a pilot randomised controlled trial
(RCT) of patient direct access to physiotherapy
in four general practices and one physiotherapy
service in one English town.
▪ It provides evidence for the feasibility and safety
of patient direct access to physiotherapy
services.
▪ Observed recruitment and follow-up rates can
inform a future full RCT.
▪ As a pilot RCT, analyses of clinical and cost out-
comes are exploratory.
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Patient direct access to UK National Health Service
(NHS) physiotherapy is one potential solution, allowing
patients to refer themselves to physiotherapy services
rather than referral being initiated by the GP. Despite
reported beneﬁts from observational research such as
reduction in GP workload particularly for repeat consulta-
tions,5 improved access for patients,6 7 and reductions in
costs,8 9 progress towards widespread provision of patient
direct access to NHS physiotherapy has been slow.
In the UK healthcare under the NHS is free at point
of delivery, meaning that patients do not pay fees to see
NHS GPs, NHS physiotherapists or to access specialist
NHS hospital services. However, patients can access
private healthcare providers but these costs must be met
in full by the patient or by employer provided or person-
ally bought private medical insurance. Around 11% of the
UK population has some private medical insurance but
many of these policies exclude many health conditions.10
The NHS is therefore the predominant healthcare pro-
vider in the UK. Legislation has allowed patients to access
physiotherapists directly since 1977 but in the NHS ser-
vices are commissioned by clinical commissioning groups,
allocated funds from the Department of Health, and
patient direct access to physiotherapy is only available in
some areas of the UK. The physiotherapists involved in
this pilot trial did not have advanced practice roles and so
were not able to order and interpret investigations or
make referrals to hospital specialist services.
A speciﬁc recommendation in the recent Primary
Care Workforce Commission is to investigate whether
direct access to physiotherapy for some conditions
makes cost-effective use of NHS resources.11
The aim of the STEMS pilot trial was to assess the
feasibility of a future large trial to compare the clinical
and cost-effectiveness of the addition of patient direct
access to physiotherapy versus continuing with usual
GP-led care alone for adults with common musculoskel-
etal problems. The speciﬁc objectives of this pilot trial
comprised process objectives to assess the feasibility of a
future large cluster randomised trial, and research objec-
tives that focused on exploratory analysis of clinical out-
comes and costs.
Process objectives
i. To assess the engagement of GP practices and
physiotherapy services to participate and stay in the
trial through follow-up.
ii. To assess the feasibility of establishing a patient’s
direct access to physiotherapy pathway.
iii. To develop and test approaches to marketing the
direct access pathway to ensure a sufﬁcient propor-
tion of patients use the pathway.
iv. To estimate recruitment rates in the control and
intervention practices.
v. To explore any evidence of selection bias in the
control and intervention practices.
vi. To estimate follow-up rates at each follow-up time
point.
Research objectives
i. To explore changes in the proposed main trial
primary outcome measure (physical health mea-
sured using the 36-item Short Form Health Survey
(SF-36)v2 Physical Component Summary (PCS)).
ii. To explore changes in other outcome measures
(overall perceived change, SF-36v2 Mental
Component Summary, pain self-efﬁcacy, quality of
life, understanding of the condition, experience of
care, and convenience and accessibility of services).
iii. To provide an exploratory estimate of costs, both
healthcare and societal costs.
iv. To estimate the parameters needed for a realistic
sample size calculation for a future large cluster
RCT.
v. To explore the use of willingness to pay methodology
to capture the strength of patient preferences for
self-referral to NHS physiotherapy. This analysis will
be reported in a separate future paper.
METHODS
Design and setting
STEMS was a pilot, pragmatic, two-arm parallel, non-
inferiority, cluster RCT in four general practices in one
town in Cheshire, UK, referring patients to a local NHS
physiotherapy service, which did not offer the patient
direct access to care prior to the set-up of the STEMS
trial. The methods have been described in full in the
STEMS trial protocol,12 but are summarised below.
Randomisation
General practices were randomised using computer-
generated random numbers stratiﬁed by the practice
size (small or large, based on the average number of
patients registered per practice at the start of the pilot
trial) in the ratio 1:1 to continue to offer GP-led care
alone as usual care (n=2) or GP-led care plus the addi-
tion of a new pathway permitting patient direct access to
an existing NHS physiotherapy service. Patients followed
the care to which their practice was randomised and
were recruited through identical patient information
explaining that musculoskeletal services were being eval-
uated using patient self-reported clinical outcomes and
medical record review. Patient direct access to physio-
therapy was not available to patients registered with
control practices. The study statistician was blinded to
practice allocation.
Participants
Data were collected from individual participants who
were eligible if they were 18 years or over and presenting
to their general practice or physiotherapy service with a
musculoskeletal condition. Patients who were undergo-
ing palliative care, had severe learning disabilities, were
housebound or in nursing home accommodation or
unable to communicate in English were not eligible to
take part.
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Potentially eligible participants were identiﬁed when
they presented to the general practice or physiotherapy
service and were mailed a study pack including the ﬁrst
questionnaire. Follow-up data collection from consenting
participants was via participant self-completion postal
questionnaires at 2, 6 and 12 months and through
review of general practice and physiotherapy records.
Setting up the patient direct access to physiotherapy
pathway
Physiotherapists attended a 1-day training programme to
prepare them for providing care to patients who self-refer,
including topics such as prevalence and identiﬁcation of
red ﬂags, physical and musculoskeletal manifestations of
underlying medical pathology and review of common
over-the-counter and prescribed medications for muscu-
loskeletal pain.12 Physiotherapists also attended regular
mentoring meetings with a senior physiotherapist in the
participating physiotherapy service.
The patient’s direct access pathway began 8 weeks
prior to the start of participant recruitment to the study
in order to allow familiarisation with receiving and man-
aging patients using the direct access pathway. All refer-
rals (GPs or patient self-referral) were triaged using
existing physiotherapy service criteria and were classiﬁed
as urgent, routine or inappropriate for physiotherapy.
Whether self-referring or GP referred to physiotherapy
patients received equitable treatment such as the length
of wait to ﬁrst appointment once logged on the physio-
therapy administration system. As this trial investigated
the addition of direct access to physiotherapy, the
physiotherapy care provided was determined by clinical
need and assessment ﬁndings and was therefore consist-
ent with routine practice and did not differ for patients
in the different arms of the trial.
In order to ensure that patients were aware of the new
direct access pathway, all adult registered patients at the
two intervention practices (n=8222) were individually
mailed an information letter about direct access. Posters,
ﬂyers and self-referral forms were readily available in
intervention practices. Even with the offer of self-referral,
we anticipated that some patients would continue to
consult their GP or practice nurse, therefore in the inter-
vention practices, patients could access physiotherapy
either by traditional written referral, be recommended to
self-refer (GP or nurse ‘recommended’ self-referral) or
choose to self-refer to physiotherapy without contacting
their GP practice (‘true’ self-referrers).
Safety of the pathway was explored by the number of
adverse events reported and by systematically searching
for diagnostic codes of a wide range of pathologies
(including cancer, fractures, joint infections and stroke)
in the medical records of participants who used the
direct access pathway.
Outcomes and analysis
As a pilot trial, the emphasis was on process outcomes to
establish the feasibility for a full trial. Outcomes were
collected from several sources. Anonymised process
outcome data were collected from physiotherapy service
records and self-referral forms. Individual participants
provided data on their characteristics, clinical outcomes
and costs through self-completed questionnaires follow-
ing recruitment to the research and at 2, 6 and
12 months. Key outcome data were sought from non-
responders through minimum data collection (MDC). A
list of outcomes is provided in table 1. To ensure trans-
parency in analyses, a statistical analysis plan was devel-
oped and approved by the Trial Steering Committee
(TSC) prior to the ﬁnal analysis. Since this was a pilot
trial, the aim of all analyses was to decide if a main trial
is feasible and desirable, in addition to ﬁnalising the
sample size for a future main trial. Descriptive summar-
ies report the number of participants identiﬁed and
recruited, along with the number of participants fol-
lowed up at each time point. Withdrawals (and where
possible, reasons for withdrawals) are reported.
Anonymised data on key baseline characteristics (age,
gender and Index of Multiple Deprivation) of those who
were invited but did not participate are compared with
those who did participate.
The feasibility of offering direct access was assessed,
including the number of participants who were referred
to physiotherapy by their GP, those who were ‘recom-
mended self-referrals’ (prompted by their GP or prac-
tice nurse to refer) and those who were ‘true
self-referrals’ and the waiting time to the ﬁrst physiother-
apy appointment.
Analyses were conducted for the clinical outcomes, but
this was treated as exploratory and mainly descriptive. A
baseline table compared the demographic and clinical
characteristics of participants. Since this is a pilot trial with
only four clusters randomised, some imbalance between
participants in each of the treatment arms on one or more
baseline characteristics was anticipated. The baseline table
was scrutinised for any serious imbalances in observable
baseline variables and the trends of the imbalance if any.
Recruitment rates were also estimated and compared
between the control and intervention arms.
All continuous variables were summarised using mean,
SD, median and IQR as appropriate and the frequency
and percentages of observed levels reported for all cat-
egorical measures. As this was a pilot trial, no emphasis
was put on the p values for inferential statistical tests
conducted. A mixed-effect model, which allowed all
available data at all the four time points to be used and
accounted for missing data and clustering effect, was
used to estimate a two-sided 95% CI to show a credible
range for the true difference in the SF-36v2 PCS sub-
scale between intervention and the control arms. The
model was adjusted for key patient-level baseline
characteristics (age, area-level deprivation and wide-
spread pain (from manikin data)) and a random effect
for the GP practices and included a treatment-by-time
interaction to obtain the estimates of treatment effect
(and 95% CI) at each follow-up time point (2, 6 and
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12 months). Analyses of the secondary outcomes were
performed similarly.
The pilot data provided information on the para-
meters needed for a realistic sample size calculation
(follow-up rates, average cluster size) for a future, main
cluster RCT. Previous research in musculoskeletal disor-
ders has estimated a minimal clinically important differ-
ence from 2 to 4 points for the SF-36v.2 PCS subscale
which should be used to inform the non-inferiority
margin of any future main trial.17–20 Previous research
and our own previous trials have also estimated the
intracluster correlation coefﬁcient (ICC) for the PCS to
inform a future main trial.
The economic analysis was exploratory, with the aim
to inform the design of a full cost-utility analysis along-
side a future main trial. All patients were asked to com-
plete the ﬁve-level version of the EuroQoL-5D (EQ-5D)
questionnaire at baseline, 6 months and 12 months in
Table 1 STEMS pilot trial questionnaire measures
Baseline 2 months 6 months 12 months
Likely primary outcome measure for main trial
Physical function SF-36v2 Physical Component Summary13 http://
www.sf-36.org/
(the higher the score the better the physical
health)
✓ ✓ ✓ ✓
Secondary outcome measures
Overall change in condition Global Assessment of Change since baseline—
single question
✗ ✓ ✓ ✓
Mental health SF-36v2 Mental Component Summary13 http://
www.sf-36.org/
(the higher the score the better the mental
health)
✓ ✓ ✓ ✓
Quality of life EuroQol EQ-5D-5L http://www.euroqol.org14
(the higher the score the better the quality of life)
✓ ✓ ✓ ✓
Self-efficacy Pain Self-Efficacy Questionnaire15
(10-item scale: 0=not at all confident,
60=completely confident despite pain)
✓ ✓ ✓ ✓
Understanding of condition General Practice Assessment Questionnaire
enablement subscale16
(very well, unsure, not very well)
✓ ✓ ✓ ✗
Experience of consultations General Practice Assessment Questionnaire
communication16
(Based on 5 items represented as a percentage
of the maximum possible score 100)
✓ ✓ ✓ ✗
Convenience of services Single question
(0–10 Numerical Rating Scale: 0=not at all
convenient, 10=very convenient)
✓ ✓ ✓ ✗
Satisfaction with services Single question
(0–10 Numerical Rating Scale: 0=not satisfied,
10=very satisfied)
✓ ✓ ✓ ✗
Baseline measures
Demographics Gender, date of birth, ethnicity, education, health
literacy, employment status, socioeconomic
status (recent paid job title, housing)
✓ ✗ ✗ ✗
Baseline risk of persistent
problems
STarT Musc tool (draft tool developed at Keele
University to identify patients’ risk of persistent
pain and disability)
✓ ✗ ✗ ✗
Pain location Body manikin ✓ ✗ ✗ ✗
Pain duration Single question about duration of pain ✓ ✗ ✗ ✗
Comorbidities Single question ✓ ✗ ✗ ✗
Economic outcomes
Further healthcare usage Consultations, investigations, procedures,
admissions, over-the-counter medications
✗ ✗ ✓ ✓
Work absence Single question (number of days) ✓ ✓ ✓ ✓
Presenteeism Single work performance question
(0–10 Numerical Rating Scale: 0=not at all
affected, 10=unable to do my job)
✓ ✓ ✓ ✓
SF-36, 36-item Short Form Health Survey.
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order for the quality-adjusted life years (QALYs) over
the 12-month time period to be calculated for each par-
ticipant. The QALYs combine information on
health-related quality of life and survival. A cost-
consequence analysis is reported, describing all the
important results relating to costs and consequences.
Analyses were mainly descriptive and total costs and out-
comes were summarised using means and 95% CIs. The
base case cost analysis adopted a NHS and personal
social services (PSS) perspective. A broader costing per-
spective was considered in a sensitivity analysis, taking
into account NHS/PSS costs and patients’ personal
expenditure costs. Costs associated with work loss were
also reported as part of the cost-consequence analysis.
Sample size
As this was a pilot trial, formal sample size calculation
was not carried out. The sample size was based on the
number of patients we anticipated could be recruited
within 6 months and that was sufﬁciently large to esti-
mate the key feasibility parameters (eg, recruitment and
retention) to a sufﬁcient degree of accuracy (<10% in
the rates). We aimed to recruit 960 participants at base-
line, over a period of 6 months and achieve at least 80%
follow-up rate (n=768) at 6 months.
Trial registration
The STEMS pilot trial is registered at Current
Controlled Trials ISRCTN23378642.
RESULTS
A ﬂow chart showing the ﬂow of practices (units of ran-
domisation) and ﬂow of individual participants is shown
in ﬁgure 1. As can be seen one of the control practices
was considerably larger than the other randomised prac-
tices resulting in more participants in the control arm in
this pilot trial.
Process results
Engagement of GP practices and the physiotherapy service
Of the ﬁve GP practices approached, four participated
with three full-time equivalent GPs at each of the two
intervention practices and ﬁve and two in the control
practices. In the physiotherapy service, of the physiothera-
pists who undertook the STEMS training programme,
four worked in the clinic local to the participating
general practices and delivered care to patients using the
direct access pathway (NHS Agenda for Change band 7
(n=1), band 6 (n=2) and band 5 (n=1)). Agenda for
Change is the NHS Terms and Conditions of Service and
determines salary scales for NHS staff.
Feasibility of the patient direct access pathway
Of the participants in the STEMS pilot trial (n=978), a
total of 256 (26.2%) accessed physiotherapy care during
the study period, 152 (35.8%) in the intervention arm
and 104 (18.8%) in the control arm. Of the 152 who
accessed physiotherapy care in the intervention arm,
142 (93.4%) were self-referrals (comprising 98 (69%)
‘recommended’ and 44 (31%) ‘true’ self-referrals).
Comparisons to service-level data (which may not be
entirely comparable, due to the introduction of new
administration software in the physiotherapy service),
from the same period 1 year prior to start of direct
access suggests one practice in the intervention arm had
broadly similar rates of patients accessing physiotherapy
care, whereas the other had a substantial increase once
the direct access pathway had been introduced. The
referral rates to physiotherapy prior to the trial showed
considerable variation between the four participating
practices. The practice in which referrals increased fol-
lowing the introduction of patient direct access previ-
ously referred 32.6 referrals per annum per 1000
registered adults compared with the other practices
(59.3, 69.5 and 92.4 referrals per annum per 1000 regis-
tered adults). However, the median (IQR; range) overall
waiting time in the physiotherapy service (applying to all
patients in the service, as all patients joined one waiting
list), from logging of the referral to ﬁrst appointment,
was 28 (13–36; 0–73) days prior to the introduction of
direct access and 26 (17–42; 0–182) days during the
direct access period of the trial. Of the patients using
the direct access pathway, triaging according to pre-
existing service criteria classiﬁed 23% (n=159) cases as
urgent, 73% (n=507) as routine and 4% (n=25) as
unsuitable for physiotherapy.
Marketing of the direct access pathway was successful.
We aimed to ensure a minimum of 20% of the physio-
therapy caseload during the pilot trial, from intervention
arm practices, was through direct access. Using anon-
ymised physiotherapy service data, of 765 patients regis-
tered at intervention practices and accessing care for
10 months following the introduction of the direct
access pathway, 691 (90.3%) used the pathway (compris-
ing 515 (74.5%) ‘recommended’ and 176 (25.5%) ‘true’
self-referrals).
Safety of direct access
No adverse events were reported by GPs or physiothera-
pists during the pilot trial. Review of medical records
identiﬁed no evidence of missed serious pathology in
patients who directly accessed physiotherapy.
Participant recruitment and retention
Of 2696 participants invited to take part in the data col-
lection, 978 (36%) participated (425 (44%) in the inter-
vention practices and 553 (57%) in the control
practices). Recruitment was completed within 6 months
( June to December 2013). Response rates were as
follows: 74.3% at 2 months (intervention 70.4%, control
77.4%), 78.4% at 6 months (intervention 76.7%, control
79.8%) and 70.7% at 12 months (intervention 69.4%,
control 71.6%). MDC was included at 6 and 12 months
only resulting in higher response rates at these time
points.
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Comparability of baseline characteristics
The baseline characteristics of participants (table 2)
were comparable in the two arms of the trial and there
was no evidence of selection bias.
Baseline characteristics by physiotherapy access method
The baseline characteristics of musculoskeletal consul-
ters and study participants who did and did not access
physiotherapy care in each trial arm are shown in online
supplementary table S1. This shows that the character-
istics of patients referred to physiotherapy by their GP or
who accessed physiotherapy through self-referral were
similar. However, ‘true’ self-referrers were more likely to
be female and less likely to be in paid work. In addition,
those in the most socioeconomically deprived group
were less likely to use ‘true’ self-referral, although the
numbers were very small.
Research objectives
Exploratory analysis of key clinical outcomes
The descriptive statistics (mean and SD or frequency
and %) for outcomes at each data collection time point
are displayed in table 3.
Patients’ physical health measured using the SF-36
PCS is the anticipated primary clinical outcome for a
future main trial. Higher scores represent better physical
Figure 1 STEMS pilot trial flow
chart. GP, general practitioner;
MSK, musculoskeletal.
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health. In this exploratory analysis very similar scores
over time in participants in both arms of the trial were
seen. The adjusted mean difference between groups and
95% CI showed estimates of effect at 2 months −0.14
(95% CI −1.02 to 0.74), at 6 months −0.28 (−1.35 to
0.79) and at 12 months 0.12 (−1.27 to 1.51). The lower
limit of the two-sided 95% CI for intervention versus
control mean difference was >−2, the smallest expected
standard treatment effect for the outcome (SF-36 PCS).
Exploratory adjusted estimates of treatment effects
for other outcomes are provided in the online
supplementary table S2.
Health economics results
EQ-5D-5L responses were available at all time points for
493 participants (281 (51%) control arm, 212 (50%)
intervention arm). Self-reported resource use data were
available at all time points for 555 participants (237
(43%) control arm, 318 (57%) intervention arm). Details
of musculoskeletal-related NHS and healthcare resource
use are reported in online supplementary table S3, with
most resource use involving consultations with GPs, phy-
siotherapists and practice nurses. Over 12 months, on
average, the control arm was associated with slightly more
GP visits, more investigations (including scans, X-rays and
MRIs) and visits to some consultants (rheumatologists
and orthopaedic surgeons) and inpatient days resulting
from surgeries. The intervention arm was however asso-
ciated with more physiotherapist visits.
Table 4 shows the disaggregated mean (SD) health-
care costs per patient for each treatment arm. The mean
NHS costs per patient were slightly cheaper in the inter-
vention arm (£940 in the intervention compared with
£951 in the control arm), with considerable uncertainty
in the estimates (95% CI of difference −363.27 to
340.83). The proportion of participants who reported
having taken time off work due to their musculoskeletal
problem was similar between the two arms of the trial
over 12 months. The intervention arm was however asso-
ciated with fewer self-reported days off work and lower
costs at 12 months follow-up. Productivity loss and costs
as a result of reduced productivity at work were higher
in the intervention group. Mean quality of life scores
(EQ-5D-5L; quality of life at baseline and follow-up and
mean QALYs) are presented in table 5. Quality of life
increased in both groups from the initial questionnaire
Table 2 Comparability of baseline characteristics
Key characteristics n*
Control
n=553
Intervention
n=425
Non-clinical characteristics
Age, mean (SD) 978 58.6 (14.6) 55.6 (15.2)
Gender: female, n (%) 978 311 (56.2) 248 (58.4)
Ethnicity: white, n (%) 958 534 (99.3) 416 (99.1)
Employment: in paid work (part-time/full-time)†, n (%) 966 244 (44.4) 190 (45.2)
Extent to which pain has affected performance at work in the past 1 month
(0–10 NRS), mean (SD)
434 4.8 (3.2) 4.9 (3.1)
Time off work (past month) due to pain, n (%) 407 74 (32.3) 54 (30.3)
Education: no qualifications, n (%) 849 133 (27.7) 104 (28.2)
Deprivation tertile (Index of Multiple Deprivation), n (%) 978
Most deprived third 161 (29.1) 103 (24.2)
Middle third 184 (33.3 145 (34.1)
Least deprived third 208 (37.6) 177 (41.7)
Health literacy: finds health information/leaflets difficult to understand, n (%) 971 311 (56.7) 242 (57.4)
Clinical characteristics
Physical health: SF-36 PCS, mean (SD) 952 35.7 (10.1) 36.6 (9.9)
Mental health: SF-36 MCS, mean (SD) 952 44.4 (13.7) 42.7 (14.0)
Bodily pain past week: severe/very severe, n (%) 976 245 (44.5) 190 (44.7)
Current episode duration: >6 weeks, n (%) 938 386 (73.0) 312 (76.3)
Widespread pain,‡ n (%) 978 193 (34.9) 137 (32.2)
Comorbidities§: for ≥2 other conditions, n (%) 978 333 (60.2) 241 (56.7)
Quality of life: EQ-5D-5L, mean (SD) 933 0.530 (0.27) 0.521 (0.28)
Pain self-efficacy (0–60), mean (SD) 895 33.4 (16.5) 32.5 (16.3)
*Nine hundred and seventy-eight participants completed the baseline questionnaire but the number of respondents for each question slightly
varies due to missing data and non-applicable cases.
†Majority of those not in paid work (34%) were retired from paid work.
‡Based on the American College of Rheumatology’s definition.21
§The conditions include high blood pressure, heart problems, stroke, diabetes, depression or anxiety, osteoporosis, arthritis, asthma or
bronchitis, liver disease, cancer and others.
EQ-5D-5L, five-level version of the EuroQoL-5D; NRS, Numerical Rating Scale; SF-36 MCS, 36-item Short Form Mental Component
Summary—the higher the score the greater mental health; SF-36 PCS, 36-item Short Form Physical Component Summary—the higher the
score the greater physical health. Pain self-efficacy scale: 10-item scale, score range=0–60 (0=not at all confident, 60=completely confident
despite pain).
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over all follow-up time points. Unadjusted mean QALYs
were slightly higher in the control arm however, QALYs
were similar in both groups arm once adjusted for clus-
tering and baseline EQ-5D-5L score. Overall, the results
show similar outcomes and costs between the interven-
tion and control arms of the trial.
DISCUSSION
No other RCTs of direct access to physiotherapy have
been conducted. This pilot RCT explored the feasibility
of a future main cluster RCT and has provided an
exploratory analysis of clinical and cost outcomes.
The results show that a future main trial is feasible
and general practices and physiotherapy services are
willing to take part. The patient recruitment target was
achieved rapidly within the estimated 6-month recruit-
ment period. Follow-up rates were good although the
follow-up at 12 months fell below our anticipated 80%.
In a future main trial we would include small patient
payments to compensate participants for their time in
completing and returning questionnaires. Cluster trials
have particular challenges including the concern about
selection bias.22 23 To minimise the risk of selection bias,
we avoided participating clinicians being involved in the
identiﬁcation and recruitment of potential participants.
The baseline characteristics of the participants showed
no evidence of selection bias, which shows that our
methods of identiﬁcation and recruitment are suitable
for use in a future main trial. We also compared the
characteristics (age, gender and area-level deprivation)
of those who returned the questionnaires and consented
to data collection to those who did not return the ques-
tionnaires. These were comparable in terms of gender
(57% vs 55%), but slightly different in terms of age
(mean (SD) of 57 (15) vs 49 (17)) and deprivation
(27% most deprived third vs 38% for those who
returned the questionnaires compared with those who
did not). Participant recruitment and retention through
long-term follow-up at 12 months was feasible and com-
pleted on time and to target. The likely primary clinical
outcome for a main trial is patients’ physical health
assessed using the SF-36 PCS.13 This performed well in
the pilot trial and exploratory analyses of clinical out-
comes showed very similar changes in patient self-
reported physical health measured in both arms of the
trial. The hypotheses for a main trial would be non-
inferiority on clinical outcomes (ie, the addition of a
patient direct access pathway to usual GP-led care would
not lead to worse clinical outcomes for patients than
usual GP-led care alone) but superiority on other key
outcomes (ie, higher patient ratings of access to services,
convenience and satisfaction with services, and reduced
costs). A future main cluster RCT with a primary clinical
outcome of physical health measured using the SF-36
PCS would require a sample size of ∼12 average-sized
general practices and a minimum of 2880 individual par-
ticipants. This is based on a margin of non-inferiority of
Ta
b
le
3
D
es
cr
ip
tiv
e
st
at
is
tic
s
(m
ea
n
an
d
S
D
or
fre
qu
en
cy
an
d
%
)
fo
r
ou
tc
om
e
m
ea
su
re
s
at
ea
ch
tim
e
po
in
t
O
u
tc
o
m
e
In
iti
al
q
u
es
tio
n
n
ai
re
2
m
o
n
th
s
6
m
o
n
th
s
12
m
o
n
th
s
C
o
n
tr
o
l
In
te
rv
en
tio
n
C
o
n
tr
o
l
In
te
rv
en
tio
n
C
o
n
tr
o
l
In
te
rv
en
tio
n
C
o
n
tr
o
l
In
te
rv
en
tio
n
P
hy
si
ca
lh
ea
lth
:
S
F
-3
6
P
C
S
,
m
ea
n
(S
D
)
35
.7
(1
0.
1)
36
.6
(9
.9
)
37
.5
(1
1.
2)
38
.5
(1
0.
5)
37
.9
(1
1.
3)
38
.7
(1
1.
2)
38
.7
(1
2.
0)
39
.7
(1
1.
2)
M
en
ta
lh
ea
lth
:
S
F
-3
6
M
C
S
,
m
ea
n
(S
D
)
44
.4
(1
3.
7)
42
.7
(1
4.
0)
45
.9
(1
2.
7)
44
.7
(1
2.
5)
46
.2
(1
3.
1)
45
.2
(1
2.
9)
45
.7
(1
3.
4)
45
.3
(1
3.
2)
O
ve
ra
ll
pe
rc
ei
ve
d
ch
an
ge
fr
om
ba
se
lin
e,
n
(%
)
C
om
pl
et
el
y
re
co
ve
re
d
−
−
8
(1
.9
)
4
(1
.4
)
28
(6
.5
)
13
(4
.0
)
30
(7
.6
)
21
(7
.2
)
M
uc
h
im
pr
ov
ed
−
−
52
(1
2.
3)
33
(1
1.
2)
44
(1
0.
1)
56
(1
7.
2)
60
(1
5.
3)
50
(1
7.
2)
S
om
ew
ha
ti
m
pr
ov
ed
−
−
81
(1
9.
2)
72
(2
4.
3)
79
(1
8.
2)
52
(1
5.
0)
59
(1
5.
0)
38
(1
3.
1)
S
am
e
−
−
17
6
(4
1.
7)
11
4
(3
8.
5)
13
3
(3
0.
7)
99
(3
0.
5)
10
6
(2
7.
0)
86
(2
9.
7)
S
om
ew
ha
tw
or
se
−
−
89
(2
1.
1)
59
(1
9.
9)
12
0
(2
7.
7)
80
(2
4.
6)
11
3
(2
8.
8)
67
(2
3.
1)
M
uc
h
w
or
se
−
−
16
(3
.8
)
14
(4
.7
)
30
(6
.9
)
25
(7
.7
)
25
(6
.4
)
28
(9
.7
)
P
ai
n
se
lf-
ef
fic
ac
y
(0
-6
0)
,m
ea
n
(S
D
)
33
.4
(1
6.
5)
32
.5
(1
6.
3)
36
.8
(1
6.
0)
37
.1
(1
6.
1)
36
.0
(1
6.
1)
36
.8
(1
6.
3)
35
.5
(1
6.
8)
38
.1
(1
6.
3)
C
on
ve
ni
en
ce
of
se
rv
ic
es
re
ce
iv
ed
,*
m
ea
n
(S
D
)
−
−
7.
1
(2
.8
)
7.
2
(2
.5
)
7.
1
(2
.5
)
7.
4
(2
.6
)
−
−
S
at
is
fa
ct
io
n
w
ith
se
rv
ic
es
re
ce
iv
ed
,†
m
ea
n
(S
D
)
−
6.
8
(2
.9
)
6.
9
(2
.9
)
7.
0
(2
.7
)
7.
2
(2
.7
)
−
−
P
ai
n
se
lf-
ef
fic
ac
y
sc
al
e:
10
-it
em
sc
al
e,
sc
or
e
ra
ng
e=
0–
60
(0
=
no
t
at
al
lc
on
fid
en
t,
60
=
co
m
pl
et
el
y
co
nf
id
en
t
de
sp
ite
pa
in
).
*0
–
10
N
um
er
ic
al
R
at
in
g
S
ca
le
:
(0
=
no
t
at
al
lc
on
ve
ni
en
t,
10
=
ve
ry
co
nv
en
ie
nt
).
†
0–
10
N
um
er
ic
al
R
at
in
g
S
ca
le
:(
0=
no
t
sa
tis
fie
d,
10
=
ve
ry
sa
tis
fie
d)
.
S
F
-3
6
M
C
S
,
36
-it
em
S
ho
rt
F
or
m
M
en
ta
lC
om
po
ne
nt
S
um
m
ar
y—
th
e
hi
gh
er
th
e
sc
or
e
th
e
gr
ea
te
r
m
en
ta
lh
ea
lth
;
S
F
-3
6
P
C
S
,
36
-it
em
S
ho
rt
F
or
m
P
hy
si
ca
lC
om
po
ne
nt
S
um
m
ar
y—
th
e
hi
gh
er
th
e
sc
or
e
th
e
gr
ea
te
r
ph
ys
ic
al
he
al
th
.
8 Bishop A, et al. BMJ Open 2017;7:e012987. doi:10.1136/bmjopen-2016-012987
Open Access
2 points from previous research,17–20 a SD of 10, a power
of 90% at a 2.5% one-sided signiﬁcance level, in a
design with three repeated measurements24 and an auto-
correlation of 0.5. The sample size has also been inﬂated
by 20% to allow for loss to follow-up, and a further
inﬂation for the design effect using an ICC of 0.0075,25
and an average cluster size of 240, allowing for a coefﬁ-
cient of variation in cluster size of 0.65.26
Exploratory health economic ﬁndings show that costs
and outcomes were similar between the intervention
Table 4 Costs per participant by trial arm over 12 months
Complete case analysis
Control (n=318)
£mean (SD)
Intervention (n=237)
£mean (SD)
NHS*
GP 106.70 (134.57) 96.97 (134.58)
Practice nurse 7.87 (33.51) 8.35 (37.93)
Physiotherapist 61.99 (165.96) 74.67 (163.36)
Orthopaedic surgeon 48.43 (114.47) 36.58 (102.54)
Rheumatologist 20.91 (87.79) 11.22 (52.17)
Acupuncturist 5.67 (50.74) 1.67 (13.63)
Chiropractor 4.28 (35.81) 1.48 (15.08)
Occupational therapist 7.89 (51.29) 5.01 (24.62)
Other healthcare professionals 33.88 (187.28) 21.67 (117.81)
Prescriptions 55.18 (118.24) 47.15 (110.41)
Surgery 422.97 (1759.25) 404.12 (1655.21)
Inpatient costs 21.57 (230.41) 75.11 (956.32)
Investigations 109.53 (329.93) 100.77 (263.43)
Injections 44.37 (164.06) 55.22 (274.33)
Private*
Physiotherapist 9.46 (55.05) 22.68 (155.41)
Orthopaedic surgeon 4.49 (34.07) 3.01 (23.74)
Rheumatologist 0 1.12 (17.27)
Acupuncturist 3.04 (30.91) 5.76 (40.60)
Chiropractor 9.13 (85.47) 6.68 (48.31)
Occupational therapist 0 0.74 (11.43)
Other healthcare professionals 3.98 (38.49) 7.63 (97.90)
Over-the-counter medicines 20.20 (52.59) 15.06 (30.06)
Work-related outcomes
Musculoskeletal-related work absence costs 740.30 (2084.75) 539.36 (2069.43)
Complete case
Total NHS cost, £ 951.25 (2050.88) 940.02 (2157.24)
Mean difference (95% CI)† 11.22 (−363.27 to 340.82)
Total healthcare costs,‡ £ 1001.56 (2068.62) 1002.72 (2230.66)
Mean difference (95% CI)† −1.15 (−358.00 to 360.32)
*Resource use and costs were related to the respondent’s MSK condition.
†Difference=intervention−control. CIs were generated using regression models for clustered data.
‡Includes costs to the NHS, private healthcare costs and over-the-counter treatment costs. In the UK, private healthcare costs are met in full
by the patient.
GP, general practitioner; MSK, musculoskeletal; NHS, National Health Service.
Table 5 EQ-5D-5L scores and QALYs at each time point
Complete case analysis
Control (n=281)
mean (SD)
Intervention
(n=212) mean (SD)
Initial questionnaire 0.565 (0.246) 0.544 (0.262)
2 months 0.600 (0.227) 0.580 (0.246)
6 months 0.602 (0.251) 0.594 (0.262)
12 months 0.615 (0.254) 0.606 (0.258)
Total 12 months QALYs (unadjusted) 0.602 (0.225) 0.589 (0.236)
Incremental QALYs (95% CI)* −0.012 (−0.053 to 0.028)
Total 12 months QALYs (adjusted for clustering and baseline EQ-5D-5L)† 0.575 0.578
Incremental QALYs 0.003
*Difference=intervention−control. CIs were generated using regression models for clustered data.
†QALYs have been adjusted for baseline differences and clustering.
EQ-5D-5L, five-level version of the EuroQol-5D; QALYs, quality-adjusted life years.
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and control arms, although there is considerable impre-
cision in the estimates due to the sample size in this
pilot RCT. Data collection through patient question-
naires was successful and indicates that a full economic
evaluation of adding a patient direct access to physio-
therapy pathway to usual GP-led primary care versus
usual GP-led primary care alone will be possible in a
future main trial. Additional costs required to set-up the
service should also be considered in a future trial.
This pilot trial suggests that adding a new patient
direct access pathway to an existing physiotherapy
service is feasible. We observed an increase in the
number of overall referrals to physiotherapy in the inter-
vention arm practices compared with service-level data
collected in the year prior to the STEMS pilot trial,
mostly from one practice, but this did not impact on the
waiting time for physiotherapy care. The level of GP
referral to physiotherapy prior to the STEMS pilot trial
was very low in this one practice compared with the
other practices. Pre-existing referral rates to physiother-
apy have previously been highlighted as a possible con-
tributing factor to subsequent increases in demand
following the introduction of patient direct access.27 An
initial increase in referrals is perhaps not surprising
bearing in mind the active marketing of the direct
access pathway that was undertaken. This type of market-
ing is unlikely to occur outside the context of a trial but
in a future main trial processes should be in place to
support participating physiotherapy services through
availability of suitably trained staff and resources for
increasing stafﬁng levels if demand increases. While no
robust claims can be made about safety given the pilot
nature of this RCT, no adverse events were reported. In
addition, our systematic search of diagnostic codes of
serious or signiﬁcant pathology in the medical records
of patients who directly accessed physiotherapy found
no evidence that the direct access pathway led to missed
serious pathologies. This is in keeping with a recent ana-
lysis of 12 976 patient visits to a US physical therapist-led
student health centre over 10 years, without a physician
referral that reported no adverse events and no missed
cases of serious pathology.28
Non-attendance rates
We also aimed to compare patient non-attendance rates
for physiotherapy before and during patient direct access,
but we were unable to achieve this as the physiotherapy
service changed the deﬁnition and processes for recording
non-attendance part way through the STEMS pilot trial.
CONCLUSION
In line with calls for research on ways to ensure patient
demand can be met in primary care, this pilot trial
shows that a future large RCT is feasible and will provide
high-quality evidence about the clinical and cost-
effectiveness of direct access to physiotherapy for
patients with musculoskeletal pain.
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